Drug Trial Radar · NCT03979820
A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
Last checked: Nov 20, 2026Latest source record: Jun 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
53
Actual
Start
Jul 31, 2019
Primary completion
Apr 8, 2020
Study completion Apr 8, 2020
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of the study is investigate the effect of escalating doses of oral tyramine on systolic blood pressure (SBP) at baseline and following an oral treatment with BI 1467335 up to 39 days at a low or high dose once daily compared to placebo and phenelzine (Nardil®) as positive control.
Conditions
- Healthy
Interventions
BI 1467335Drug
Film-coated tablet
PlaceboDrug
Film-coated tablet
Phenelzine sulfateDrug
Film-coated tablet
TyramineDrug
Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tyramine Sensitivity Factor (TSF)Time frame: At baseline (Day -11 up to Day-2) and at steady state (Day 29 up to Day 39 for the "Placebo/Placebo + Tyramine" and "10 mg BI 1467335/10 mg BI 1467335 + Tyramine" arms, Day 8 up to Day 19 for the "Phenelzine/ Phenelzine + Tyramine" arm).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA Health Sciences Onderzoekscentrum Martini
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.